You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Faricimab for treating diabetic macular oedema

  • Technology appraisal guidance
  • Reference number: TA799
  • Published:  29 June 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 141 KB)

    Published:
    29 June 2022
  • Register of interests (PDF 266 KB)

    Published:
    29 June 2022

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 154 KB)

    Published:
    24 May 2022
  • Committee papers (PDF 2.84 MB)

    Published:
    24 May 2022

Invitation to participate

  • Final scope (PDF 203 KB)

    Published:
    04 August 2021
  • Final stakeholder list (PDF 187 KB)

    Published:
    04 August 2021
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 387 KB)

    Published:
    04 August 2021
  • Equality impact assessment (Scoping) (PDF 122 KB)

    Published:
    04 August 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 223 KB)

    Published:
    21 April 2021
  • Draft matrix post referral (PDF 185 KB)

    Published:
    21 April 2021
Back to top